Mostrar el registro sencillo del ítem

dc.contributor.author
Pérez Lloret, Santiago
dc.contributor.author
Rascol, Olivier
dc.date.available
2019-12-30T06:42:08Z
dc.date.issued
2018-08
dc.identifier.citation
Pérez Lloret, Santiago; Rascol, Olivier; Efficacy and safety of amantadine for the treatment of L-DOPA-induced dyskinesia; Springer Wien; Journal of Neural Transmission. General Section; 125; 8; 8-2018; 1237-1250
dc.identifier.issn
0300-9564
dc.identifier.uri
http://hdl.handle.net/11336/93199
dc.description.abstract
l-DOPA induced dyskinesias (LIDs) may affect up to 40% of Parkinson’s disease (PD) and impact negatively health-related quality of life. Amantadine has demonstrated significant antidyskinetic effects in animal PD models and in randomized double-blind placebo-controlled trials (RCTs) in patients with PD. These effects are thought to be related to the blockade of NMDA receptors modulating cortico-striatal glutamatergic–dopaminergic interactions involved in the genesis of LIDs. There are three pharmaceutical forms of amantadine currently available in the market: an oral immediate-release (IR) formulation, which is widely available; an extended-release (ER) formulation (ADS-5102) which has been recently developed and approved by the FDA; and an intravenous infusion (IV) solution, which is not commonly used in clinical practice. RCTs with amantadine IR or ER, involving more than 650 patients have shown consistent and long-lasting reductions in LIDs. Interestingly, ADS-5102 not only reduced LIDs, but also reduced significantly at the same time the duration of daily OFF-time, a unique finding compared with other antiparkinsonian medications that usually reduce time spent OFF at the cost of worsening of LIDs. Amantadine IR might also have possible effects on other PD symptoms such as apathy or fatigue. The most common adverse reactions with amantadine are constipation, cardiovascular dysfunction including QT prolongation, orthostatic hypotension and edema, neuropsychiatric symptoms such as hallucinations, confusion and delirium, nausea and livedo reticularis. Corneal degeneration is rare but critical. In summary, amantadine immediate and extended-release are effective and safe for the treatment of LIDs.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
Springer Wien
dc.rights
info:eu-repo/semantics/restrictedAccess
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.subject
AMANTADINE
dc.subject
GLUTAMATE
dc.subject
L-DOPA
dc.subject
L-DOPA-INDUCED DYSKINESIA
dc.subject
NMDA RECEPTORS
dc.subject
Parkinson’s disease
dc.subject.classification
Neurología Clínica
dc.subject.classification
Medicina Clínica
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD
dc.title
Efficacy and safety of amantadine for the treatment of L-DOPA-induced dyskinesia
dc.type
info:eu-repo/semantics/article
dc.type
info:ar-repo/semantics/artículo
dc.type
info:eu-repo/semantics/publishedVersion
dc.date.updated
2019-10-23T14:40:49Z
dc.journal.volume
125
dc.journal.number
8
dc.journal.pagination
1237-1250
dc.journal.pais
Austria
dc.journal.ciudad
Viena
dc.journal.title
Journal of Neural Transmission. General Section
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/http://link.springer.com/10.1007/s00702-018-1869-1
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1007/s00702-018-1869-1


Archivos asociados

Documento no disponible

Comunidades y colecciones

Mostrar el registro sencillo del ítem